FDA updates medication regimen for chronic lymphocytic leukemia

Share This Post

The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual disease (MRD) data of the phase III MURANO trial, and the efficacy is significantly better In combination with bendamustine and rituximab (BR) regimen.

The MURANO study found that the efficacy of chemoimmunotherapy for CLL is related to the possibility of achieving MRD conversion, and whether the efficacy of targeted drug treatment for refractory or relapsed CLL is related to MRD conversion, because the rate of MRD conversion in these patients is relatively unknown. low.

The MURANO study showed that VenR regimen had better PFS for refractory or relapsed CLL compared with BR regimen (HR0.17), and the MRD of peripheral blood and bone marrow turned negative. The conversion of MRD to negative in the VenR group was not related to whether the patient had del (17p), non-IGVH mutation, TP53 mutation and other adverse prognostic factors. In the VenR group, 121/194 patients (62%) had MRD negative at the end of the combination therapy. At a median follow-up of 13.8 months (5.6-23.0 months), 100 patients (83%) still had negative MRD and 2 patients Progression to PD, 2 cases died of irrelevant disease, 2 cases progressed to Richter’s syndrome, 15 cases (12%) MRD turned positive [1 case MRD≥10 ^ (-2) and PD, 14 cases MRD 10 ^ (-4) ~ <10 ^ (-2) and 2 of them were PD, 1 died, and 11 still had no progress.

VenR treatment of refractory or relapsed CLL has a high degree of consistency in obtaining peripheral blood and bone marrow MRD conversion, and the status of peripheral blood MRD is significantly related to clinical efficacy. VenR can enable patients to obtain deep and durable high peripheral blood MRD conversion rate at an early stage, and has nothing to do with whether patients have adverse prognostic factors, which is significantly better than the BR program. The recurrence of MRD is only seen in a few patients and may not necessarily lead to clinical disease progression. It is suggested that VenR’s efficacy is significantly better than BR regimen, and it is currently a recommended regimen for refractory or relapsed CLL.

https://www.onclive.com/web-exclusives/fda-updates-venetoclax-cll-label-with-mrd-data

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟